PortfoliosLab logoPortfoliosLab logo
LLY vs. ZVRA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LLY vs. ZVRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eli Lilly and Company (LLY) and Zevra Therapeutics Inc. (ZVRA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, LLY achieves a 5.78% return, which is significantly lower than ZVRA's 41.18% return. Over the past 10 years, LLY has outperformed ZVRA with an annualized return of 33.45%, while ZVRA has yielded a comparatively lower -16.40% annualized return.


LLY

1D
-2.41%
1M
11.74%
YTD
5.78%
6M
10.64%
1Y
40.51%
3Y*
37.45%
5Y*
39.59%
10Y*
33.45%

ZVRA

1D
-2.47%
1M
13.76%
YTD
41.18%
6M
51.86%
1Y
35.01%
3Y*
29.54%
5Y*
-2.85%
10Y*
-16.40%
*Multi-year figures are annualized to reflect compound growth (CAGR)

LLY vs. ZVRA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
LLY
Eli Lilly and Company
5.78%40.25%33.30%60.91%34.26%66.08%31.04%16.14%40.45%17.83%
ZVRA
Zevra Therapeutics Inc.
41.18%7.43%27.33%42.70%-47.30%-22.23%84.70%-78.71%-56.05%37.29%

Correlation

The correlation between LLY and ZVRA is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.15

Correlation (10Y)
Calculated over the trailing 10-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Apr 16, 2015

0.11

Fundamentals

Market Cap

LLY:

$1.02T

ZVRA:

$761.92M

EPS

LLY:

$28.14

ZVRA:

$2.16

PE Ratio

LLY:

40.26

ZVRA:

5.85

PS Ratio

LLY:

14.08

ZVRA:

5.94

PB Ratio

LLY:

32.54

ZVRA:

3.70

Total Revenue (TTM)

LLY:

$72.25B

ZVRA:

$122.29M

Gross Profit (TTM)

LLY:

$59.75B

ZVRA:

$104.94M

EBITDA (TTM)

LLY:

$32.97B

ZVRA:

$149.15M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LLY vs. ZVRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LLY
LLY Risk / Return Rank: 7373
Overall Rank
LLY Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
LLY Sortino Ratio Rank: 7070
Sortino Ratio Rank
LLY Omega Ratio Rank: 7171
Omega Ratio Rank
LLY Calmar Ratio Rank: 7474
Calmar Ratio Rank
LLY Martin Ratio Rank: 7575
Martin Ratio Rank

ZVRA
ZVRA Risk / Return Rank: 6060
Overall Rank
ZVRA Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
ZVRA Sortino Ratio Rank: 6262
Sortino Ratio Rank
ZVRA Omega Ratio Rank: 6161
Omega Ratio Rank
ZVRA Calmar Ratio Rank: 6060
Calmar Ratio Rank
ZVRA Martin Ratio Rank: 5757
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LLY vs. ZVRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Zevra Therapeutics Inc. (ZVRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


LLYZVRADifference
Sharpe ratioReturn per unit of total volatility

+0.51

Sortino ratioReturn per unit of downside risk

+0.36

Omega ratioGain probability vs. loss probability

1.22

1.16

+0.06

Calmar ratioReturn relative to maximum drawdown

1.72

0.81

+0.91

Martin ratioReturn relative to average drawdown

4.28

1.41

+2.87

LLY vs. ZVRA - Sharpe Ratio Comparison

The current LLY Sharpe Ratio is 1.07, which is higher than the ZVRA Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of LLY and ZVRA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

LLY vs. ZVRA - Drawdown Comparison

The maximum LLY drawdown since its inception was -68.24%, smaller than the maximum ZVRA drawdown of -99.27%. Use the drawdown chart below to compare losses from any high point for LLY and ZVRA.


Loading charts...

Drawdown Indicators


LLYZVRADifference

Max Drawdown

Largest peak-to-trough decline

-68.24%

-99.27%

+31.03%

Max Drawdown (1Y)

Largest decline over 1 year

-23.64%

-43.47%

+19.83%

Max Drawdown (3Y)

Largest decline over 3 years

-34.48%

-43.47%

+8.99%

Max Drawdown (5Y)

Largest decline over 5 years

-34.48%

-74.01%

+39.53%

Max Drawdown (10Y)

Largest decline over 10 years

-34.48%

-97.85%

+63.37%

Current Drawdown

Current decline from peak

-2.41%

-96.65%

+94.24%

Average Drawdown

Average peak-to-trough decline

-19.21%

-86.41%

+67.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.49%

24.87%

-15.38%

Volatility

LLY vs. ZVRA - Volatility Comparison

The current volatility for Eli Lilly and Company (LLY) is 9.27%, while Zevra Therapeutics Inc. (ZVRA) has a volatility of 24.56%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than ZVRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LLYZVRADifference

Volatility (1M)

Calculated over the trailing 1-month period

9.27%

24.56%

-15.29%

Volatility (6M)

Calculated over the trailing 6-month period

27.16%

40.23%

-13.07%

Volatility (1Y)

Calculated over the trailing 1-year period

38.01%

62.90%

-24.89%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

32.46%

60.49%

-28.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

30.19%

81.46%

-51.27%

Dividends

LLY vs. ZVRA - Dividend Comparison

LLY's dividend yield for the trailing twelve months is around 0.57%, while ZVRA has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
LLY
Eli Lilly and Company
0.57%0.56%0.67%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%
ZVRA
Zevra Therapeutics Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

LLY vs. ZVRA - Financials Comparison

This section allows you to compare key financial metrics between Eli Lilly and Company and Zevra Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B20222023202420252026
19.80B
36.22M
(LLY) Total Revenue
(ZVRA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


LLY and ZVRA have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ZVRA has higher volatility (24.56%) compared to LLY (9.27%). In terms of maximum drawdown, LLY dropped -68.24% vs ZVRA's -99.27%.

LLY currently has the higher Sharpe Ratio (1.07 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LLY and ZVRA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer